mCRC

Oncology

12 drugs in development·5 companies·2 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
zaltrap	Sanofi (SNY)

Phase 3(1)

Drug	Company
Fruquintinib	IGM Biosciences, Inc. (IGMS)

Phase 2(8)

Drug	Company
350 mg leronlimab	CytoDyn Inc. (CYDY)
5 FU bolus	IGM Biosciences, Inc. (IGMS)
5 FU continuous	IGM Biosciences, Inc. (IGMS)
700 mg leronlimab	CytoDyn Inc. (CYDY)
Chemotherapeutic Combinations	IGM Biosciences, Inc. (IGMS)
Floxuridine	BridgeBio Oncology Therapeutics, Inc. (BBOT)
PDS01ADC	IGM Biosciences, Inc. (IGMS)
PDS01ADC	BridgeBio Oncology Therapeutics, Inc. (BBOT)

Phase 1(2)

Drug	Company
LPM6690176	IGM Biosciences, Inc. (IGMS)
me-344	Lite Strategy, Inc. (LITS)

BioSniper tracks 12 drugs in development for mCRC across 5 companies.

There are 2 clinical trials targeting mCRC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.